A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects With Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blinatumomab (Primary) ; Vincristine (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

14 Feb 2022 Planned initiation date changed from 1 Apr 2021 to 1 Jan 2022.
14 Feb 2022 Status changed from suspended to discontinued as study not moving forward.
21 Oct 2021 Status changed from not yet recruiting to suspended (PI left and changing PI).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight